Accelerometry in Follow up of Arthritis - a Pilot Study

Psoriatic Arthritis Clinical Trial

— WIAp  

Official title:

Accelerometry in Follow up of Arthritis - a Pilot Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05301621
• Other study ID #: 249395
• Status: Recruiting
• Start date: May 12, 2022
• Est. completion date: December 31, 2023

Study information

• Verified date: August 2022
• Source: Helse Forde
• Contact: Pawel Mielnik, MD, PhD
• Phone: + 4757839000
• Email: post[@]helse-forde.no
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a proof-of-concept study. The main goal is to evaluate if the accelerometry signal recorded from patients with arthritis in different disease activity stages, allows for assessment of the activity status. It will also be analysed if the accelerometry signal can be classified as registered in arthritis patients vs. registered in healthy control. Arthritis subjects will be recruited from the outpatients' clinic of the Rheumatology Department Helse Førde, Førde, Norway. Healthy control subjects will be recruited from the same administrative area as the patients and will be invited to participate via announcement on the Helse Forde Medical Trust website. Four visits to the site are planned for the arthritis group and one for the control group. The patients will be recruited in the active phase of arthritis as defined in the inclusion criteria.

The study's secondary objective is to develop methods for analysing the accelerometry signal in arthritis patients.

Description:

Study type: Observational, proof-of-concept

Objectives:

Primary objective: To evaluate if an accelerometer signal in patients with active arthritis differs from the signal taken in inactive arthritis and healthy individuals.

Secondary goals:

• To evaluate how the accelerometer signal differs depending on the disease activity status

• To elaborate the methods for analysing accelerometry in the arthritis patients

• To build knowledge and data for future studies

• To evaluate software and hardware used

Subjects and methods:

Subjects will be recruited two groups:

1. Patient with one of the following conditions: rheumatoid arthritis, psoriatic arthritis or spondyloarthritis. All subjects must satisfy inclusion/exclusion criteria.

2. Healthy individuals as defined in inclusion/exclusion criteria

The arthritis patients with active disease will be included from the outpatients clinic of the Rheumatology Department Helse Førde Medical Trust. The healthy controls will be recruited via announcement on the Helse Førde website. The maximum number of participants is estimated for 50 subjects per group.

There will be four visits in the arthritis group and a single visit in the control group.

Following data will be collected:

For both groups: age, gender, anthropometric data (high, weight, limbs length), information about comorbidities and used drugs.

Additionally, from arthritis patients disease activity data will be collected: tender joint count, swollen joint count, overall patients/physician assessment, MHAQ, BASDAI, CRP and ESR.

At all visits, ball participants will perform a set of simple physical activities such as walking, clapping, arm swinging, and moving small subjects on the table. The accelerometry signal will be recorded during those exercises.

Study management:

An interim analysis is planned after data is collected from the first 5-10 participants. The steering committee will assess study progress at this stage and decide about further study conduct.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: December 31, 2023
• Est. primary completion date: December 31, 2023
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Patients:

1. Clinical diagnosis of rheumatoid arthritis (RA), psoriatic arthritis (PsA) or spondyloarthritis (SPA).

2. Planned or newly started (within 4 weeks before baseline visit) disease-modifying treatment.

3. Disis activity defined as:

• RA - DAS28 (ESR or CRP) minimum 3.2,

• PsA - DAPSA minimum 15,

• SPA - BASDAI minimum 4.0.

4. A minimum number of tender or swollen joints:

• RA - 4/4,

• PsA - 2/2,

• SPA - not applicable.

5. Subject without comorbidities defined in the exclusion criteria.

6. Willing to participate and consent competent.

7. Over 18 years old.

Controls:

1. Without any inflammatory rheumatic disease

2. Without any comorbidity as defined in the exclusion criteria.

3. Willing to participate and consent competent.

4. Over 18 years old.

Exclusion Criteria:

Both patients and controls:

1. Chronic neurologic disorders such as multiple sclerosis, parkinsonism, active epilepsy, symptomatic peripheral neuropathy, sequels after radiculopathy or other central nervous system deficit.

2. Paresis after cerebral stroke (mild deficits or TIA can be allowed).

3. Serious heart failure (NYHA 3 or above).

4. Pregnancy.

5. Active psychotic disorder.

6. Activ alcohol or drug addiction.

7. Fast use of medicine that can significantly influence CNS function (low dose sleeping medicine 12 hours before a visit can be allowed).

8. Spinal compression fractures less than six months before baseline.

9. Other limb fractures, within 4 months before baseline if it can influence patient's mobility

10. Other medical conditions that can influence patient's mobility

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Psoriatic
• Arthritis, Rheumatoid
• Psoriatic Arthritis
• Spondylarthritis
• Spondylitis
• Spondyloarthritis

Intervention

Other:
• Akcelerometry follow up
The patients and control group will be followed up with single accelerometer.

Locations

Country	Name	City	State
Norway	Pawel Mielnik	Forde	Vestlandet

Sponsors (1)

Lead Sponsor	Collaborator
Helse Forde

Country where clinical trial is conducted

Norway, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Detection of arthritis activity status	Analysis of raw akcelerometry will be used to detect disease activity status	2023